Program
axelopran
Also written as “TD-1211”, “TD-1211 IV [C14]” and “TD-1211 PO [C14]”.
Its studies are mostly in Opioid-Induced Constipation · Squamous Cell Carcinoma of Head and Neck · Constipation, led by Glycyx Therapeutics.
Furthest: phase 2, since Dec 22, 20098 company-led studies, 1 open or runningNext primary completion: Aug 31, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Glycyx Therapeutics | 81 open or running | phase 2since Dec 22, 2009 | Dec 22, 2009 | Aug 31, 2027phase 2 · NCT07662720 |
Also a collaborator on its studies: Zymeworks.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 22, 2009First study: phase 2 study in Opioid-Induced ConstipationFirst studyNCT01040637 · 102 enrolled · United States
- Mar 30, 2011Phase 2 study in Opioid-Induced ConstipationNCT01333540 · 69 enrolled · United States
- Jul 19, 2011Phase 2 study in Opioid-Induced ConstipationNCT01401985 · 95 enrolled · United States
- Oct 24, 2011Phase 2 study in Opioid-Induced ConstipationNCT01459926 · 217 enrolled · United States
- Mar 23, 2012Phase 1 study in HealthyNCT01568411 · 20 enrolled · United States
- Jul 31, 2012Phase 1 study in ConstipationNCT01655771 · 47 enrolled · United States
- Oct 2, 2012Phase 1 study in Opioid-Induced ConstipationNCT01702194 · 10 enrolled · United States
- Jun 12, 2026Phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT07662720 · 18 planned
Ahead
- Aug 31, 2027Primary completion: phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT07662720
TargetBeta
OPRM1 →read by rule
“Mu opioid receptor antagonist”ChEMBL 37, by rule
Other programs on OPRM1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Oxycodonerule | Mundipharma | phase 4 | 72 |
| Naltrexonerule | orexigen-therapeutics-inc | phase 4 | 42 |
| nalmefenerule | H. Lundbeck | phase 4 | 20 |
| Nalbuphinerule | Trevi Therapeutics | phase 4 | 20 |
| Methadonerule | Merck | phase 4 | 16 |
| cebranopadolrule | Tris Pharma | phase 3 | 18 |
| Alfentanilrule | Sichuan Kelun Pharmaceutical | phase 1 | 1 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07662720Squamous Cell Carcinoma of Head and Neck | 2 | Not yet recruiting | Aug 31, 2027 | 18 |
| NCT01702194Opioid-Induced Constipation · United States | 1 | Completed | Feb 2013 | 10 |
| NCT01655771Constipation · United States | 1 | Completed | Feb 2013 | 47 |
| NCT01568411Healthy · United States | 1 | Completed | Jun 2012 | 20 |
| NCT01459926Opioid-Induced Constipation · United States | 2 | Completed | May 2012 | 217 |
| NCT01401985Opioid-Induced Constipation · United States | 2 | Completed | May 2012 | 95 |
| NCT01333540Opioid-Induced Constipation · United States | 2 | Completed | May 2012 | 69 |
| NCT01040637Opioid-Induced Constipation · United States | 2 | Completed | Oct 2010 | 102 |
How it is read
Names in the registry
- “TD-1211”, 15 entries
- “axelopran”, 1 entry
- “TD-1211 IV [C14]”, 1 entry
- “TD-1211 PO [C14]”, 1 entry
- “TD-1211+ itraconazole”, 1 entry
Conditions, from the studies’ own filings
- Opioid-Induced Constipation, 5 studies
- Squamous Cell Carcinoma of Head and Neck, 1 study
- Constipation, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.